Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
NCT01443442
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
23
Enrollment
OTHER
Sponsor class
Conditions
Allergic Conjunctivitis
Interventions
DRUG:
bepotastine besilate, 1.5%
DRUG:
Loteprednol etabonate
Sponsor
Southern California College of Optometry at Marshall B. Ketchum University